Submissions for variant NM_000256.3(MYBPC3):c.3005G>A (p.Arg1002Gln)

gnomAD frequency: 0.00004  dbSNP: rs727504235

Total submissions: 7

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000154201	SCV000203853	uncertain significance	not specified	2019-04-05	criteria provided, single submitter	clinical testing	The p.Arg1002Gln variant in MYBPC3 has been reported in 3 individuals with HCM (Niimura 2002, Ho 2009 and LVOD unpublished data). This variant was also identified by our laboratory in 1 individual with DCM and in 1 individual with giant right atrium and arrhythmia (LMM unpublished data). In addition, this variant was identified in 4/62092 European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org). Arginine (Arg) at position 1002 is not conserved in evolutionarily distant species and the change to glutamine (Gln) is present in several birds. Additional computational prediction tools do not provide strong support for or against an impact to the protein. In summary, while the clinical significance of the Arg1002Gln variant is uncertain, the presence of the variant amino acid in multiple bird species suggests that it is more likely to be benign.,The Arg1002Gln variant in MYBPC3 has been reported in 3 individuals with HCM (Niimura 2002, Ho 2009 and LVOD unpublished data). This variant was also identified by our laboratory in 1 individual with DCM and in 1 individual with giant right atrium and arrhythmia (LMM unpublished data). In addition, this variant was identified in 4/62092 European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org). Arginine (Arg) at position 1002 is not conserved in evolutionarily distant species and the change to glutamine (Gln) is present in several birds. Additional computational prediction tools do not provide strong support for or against an impact to the protein. In summary, while the clinical significance of the Arg1002Gln variant is uncertain, the presence of the variant amino acid in multiple bird species suggests that it is more likely to be benign.
GeneDx	RCV000766363	SCV000208142	uncertain significance	not provided	2023-08-25	criteria provided, single submitter	clinical testing	Reported in individuals with HCM and DCM, and in one individual with sudden unexplained death in infancy (Niimura et al., 2002; Ho et al., 2009; Coppini et al., 2014; Burns et al, 2017; Walsh et al., 2017; Cirino et al., 2017; Dewar et al., 2017); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 21415409, 15115610, 24503780, 11815426, 20031602, 28790153, 28679633, 29030401, 25524337, 28807990, 27532257, 28986452, 33782553, KrylovaNS2020, 33673806, 35653365)
Invitae	RCV000688819	SCV000816443	uncertain significance	Hypertrophic cardiomyopathy	2023-12-18	criteria provided, single submitter	clinical testing	This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1002 of the MYBPC3 protein (p.Arg1002Gln). This variant is present in population databases (rs727504235, gnomAD 0.01%). This missense change has been observed in individual(s) with clinical features of MYBPC3-related conditions (PMID: 11815426, 27532257, 28790153, 28807990, 29030401, 33673806, 33782553). ClinVar contains an entry for this variant (Variation ID: 177622). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Color Diagnostics, LLC DBA Color Health	RCV001190892	SCV001358525	uncertain significance	Cardiomyopathy	2023-03-02	criteria provided, single submitter	clinical testing	This missense variant replaces arginine with glutamine at codon 1002 of the MYBPC3 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been performed for this variant. This variant has been reported in several individuals affected with hypertrophic cardiomyopathy (PMID: 11815426, 28790153, 27532257, 32841044, 33495597; Burns, thesis 2019) and in an infant affected with sudden death (PMID: 28807990). This variant has also been identified in 16/267108 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario	RCV001190892	SCV002042190	uncertain significance	Cardiomyopathy	2021-10-04	criteria provided, single submitter	clinical testing
Ambry Genetics	RCV002433671	SCV002748675	uncertain significance	Cardiovascular phenotype	2022-07-25	criteria provided, single submitter	clinical testing	The p.R1002Q variant (also known as c.3005G>A), located in coding exon 29 of the MYBPC3 gene, results from a G to A substitution at nucleotide position 3005. The arginine at codon 1002 is replaced by glutamine, an amino acid with highly similar properties. This alteration has been detected in hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) and sudden unexplained death (SUD) cohorts; however, clinical details are limited (Niimura H et al. Circulation, 2002 Jan;105:446-51; Burns C et al. Circ Cardiovasc Genet, 2017 Aug;10; Dewar LJ et al. Circ Cardiovasc Genet, 2017 Aug;10; Ho CY et al. Circ Cardiovasc Genet, 2009 Aug;2:314-21; Coppini R et al. J. Am. Coll. Cardiol., 2014 Dec;64:2589-2600; Cirino AL et al. Circ Cardiovasc Genet, 2017 Oct;10; Walsh R et al. Genet. Med., 2017 02;19:192-203; Oakley CE et al. Cell Res., 2004 Apr;14:95-110). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Blueprint Genetics	RCV000208257	SCV000264038	likely pathogenic	Primary familial hypertrophic cardiomyopathy	2015-01-26	flagged submission	clinical testing